ZEUS-CVOT
Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
- Stadium
- followup
- Middel
- Ziltivekimab
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 8 oktober 2021
- Last Patient In
- 10 april 2024
- Last Patient Last Visit
- 26 juni 2026
National Lead
prof. dr. J.H. Cornel
Cardioloog
Contact Kantoor
